会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Preparation of ascorbic acid 2-phosphate and of 5,
6-isopropylideneascorbic acid and potassium magnesium l-ascorbate
2-phosphate as an advantageous salt of l-ascorbic acid 2- phosphate
    • 作为1-抗坏血酸2-磷酸盐的有利盐,制备抗坏血酸2-磷酸酯和5,6-异丙基亚甲基抗坏血酸和1-抗坏血酸钾钾2-磷酸酯
    • US4999437A
    • 1991-03-12
    • US486755
    • 1990-03-01
    • Walter DoblerJoachim PaustRoland Betz
    • Walter DoblerJoachim PaustRoland Betz
    • C07F9/655
    • C07F9/65515
    • Ascorbic acid 2-phosphate is prepared by reacting ascorbic acid or an ascorbic acid derivative with POCl.sub.3 in the presence of a tertiary amine in a suitable aqueous solvent at from -10.degree. to 25.degree. C. while maintaining a pH of about 8-13.5 with KOH during the entire phosphorylation reaction and then isolating the ascorbic acid 2-phosphate, by a process in which an aqueous solution of a magnesium compound is added to the reaction mixture obtained in the phosphorylation, without prior treatment with an ion exchanger, until the formation of crystalline KMg PO.sub.4 is complete, the KMgPO.sub.4 which is crystallized out is separated off, the resulting filtrate is evaporated down at a pH of from 6 to 11 and/or from 0.1 to 5 times the amount, based on the evaporated filtrate, of a lower primary alkanol or acetone is added and the stirred mixture is cooled until KCl has completely crystallized out, and the ascorbic acid phosphate is isolated in a conventional manner from the reaction solution obtained by separating off KCl and substantially freed from inorganic salts. It is particularly advantageous if the ascorbic acid 2-phosphate is isolated in the form of the novel potassium magnesium ascorbate 2-phosphate, which is also claimed.The process is particularly advantageous if the ascorbic acid derivative used is 5,6-isopropylideneascorbic acid which has been obtained by reacting ascorbic acid with acetone in the presence of oleum. The process is particularly important for the preparation of L-ascorbic acid 2-phosphate.
    • 抗坏血酸2-磷酸酯通过使抗坏血酸或抗坏血酸衍生物与POCl 3在叔胺存在下,在-10℃至25℃的合适的水性溶剂中反应制备,同时保持约8-13.5的pH,同时用 KOH,然后通过将镁化合物的水溶液加入到磷酸化中获得的反应混合物中而不用离子交换剂进行预处理的方法分离出抗坏血酸2-磷酸酯,直到形成 结晶KMg PO4完成后,将结晶出来的KMgPO4分离出来,所得滤液按照蒸发滤液的6至11和/或0.1至5倍的pH蒸发掉, 加入低级主链烷醇或丙酮,将搅拌的混合物冷却直至KCl完全结晶出来,并以常规方式从得到的反应溶液中分离抗坏血酸磷酸酯 通过分离KCl并基本上从无机盐中除去。 特别有利的是,抗坏血酸2-磷酸酯以新的抗坏血酸钾2-磷酸2-钾的形式被分离,这也是要求保护的。 如果所使用的抗坏血酸衍生物是在发烟硫酸存在下使抗坏血酸与丙酮反应获得的5,6-异亚丙基抗坏血酸,该方法是特别有利的。 该方法对于制备L-抗坏血酸2-磷酸酯尤为重要。
    • 2. 发明授权
    • Preparation of cyclic acetals of 3-formyl-2-butenyltriphenylphosphonium
chloride
    • 制备3-甲酰基-2-丁烯基三苯基氯化鏻的环状缩醛
    • US5344995A
    • 1994-09-06
    • US85903
    • 1993-07-06
    • Wolfgang KrauseJoachim PaustWalter DoblerHagen Jaedicke
    • Wolfgang KrauseJoachim PaustWalter DoblerHagen Jaedicke
    • C07F9/54C07D319/06C07F9/655C07C43/305C07C43/313
    • C07F9/6552C07D319/06
    • An improved process for preparing cyclic acetals of 3-formyl-2-butenyltriphenylphosphonium chloride by acetalization of 3-formyl-2-butenyl acetate with an aliphatic 1,3-diol, conversion of the resulting 4-acetoxy acetal into the corresponding 4-hydroxy acetal, Vilsmeier chlorination to give the corresponding 4-chloro acetal and subsequent reaction with triphenylphosphine entails carrying out the first 3 steps in an aliphatic or cycloaliphatic hydrocarbon or mixture of hydrocarbons with 6-8 carbons and the reaction with triphenylphosphine in an alkanol with 1-3 carbons and/or in aliphatic or cycloaliphatic hydrocarbon with 6-8 carbons or a corresponding mixture of hydrocarbons. The process is particularly advantageous when conversion of the 4-acetoxy acetal into the 4-hydroxy acetal is carried out with an aqueous alkali metal hydroxide solution in the presence of phase-transfer catalysts, and the first three, or all four, reaction stages are carried out in the same C.sub.6 -C.sub.8 -hydrocarbon.
    • 通过用脂肪族1,3-二醇缩醛化3-甲酰基-2-丁烯基乙酸酯与3-甲酰基-2-丁烯基三苯基氯化鏻的环状缩醛的改进方法,将得到的4-乙酰氧基缩醛转化为相应的4-羟基 缩醛,Vilsmeier氯化,得到相应的4-氯缩醛,随后与三苯基膦反应需要在脂族或脂环族烃或碳原子数为6〜8的混合物中进行前3个步骤,并与三苯基膦在链烷醇中与1- 3个碳原子和/或具有6-8个碳原子的脂族或脂环族烃或相应的烃混合物。 当在相转移催化剂存在下,用碱金属氢氧化物水溶液进行4-乙酰氧基缩醛转化为4-羟基缩醛时,该方法是特别有利的,而前三个或所有四个反应阶段是 在相同的C6-C8-烃中进行。
    • 4. 发明授权
    • Epimerization of sugars, in particular of D-arabinose to D-ribose
    • 糖异构化,特别是D-阿拉伯糖对D-核糖
    • US4778531A
    • 1988-10-18
    • US68171
    • 1987-06-30
    • Walter DoblerHansgeorg ErnstJoachim Paust
    • Walter DoblerHansgeorg ErnstJoachim Paust
    • C07B61/00C07H3/00C07H3/02C07H1/00C13J1/06
    • C07H3/02
    • Pentoses and hexoses are epimerized by heating sugar dissolved in a solvent in the presence of a molybdenum(VI) compound, by an improved process in which, for the preparation of a sugar having cis OH groups in the 2- or 3-position, of the formula Ia or Ib ##STR1## where R is one of the radicals ##STR2## a homogeneous solution of the corresponding sugar of the formula IIa or IIb ##STR3## is heated to 75.degree.-100.degree. C. in the presence of from 30 to 200 mol %, based on sugar used, of a metal salt of the formula (III)MeX.sub.2 (III)where Me is Mg, Ca, Sr, Ba or Zn and X is Cl or Br, which may or may not contain water of crystallization, and in the presence of from 2 to 20 mol %, based on the sugar used, of a molybdenum(VI) compound.The process is particularly important for the preparation of D-ribose, which is required as an intermediate for vitamin B.sub.2.
    • 戊糖和己糖通过加热溶解在钼(VI)化合物存在下的溶剂中的糖进行差向异构化,其中通过改进方法,其中为了制备在2-或3-位具有顺式OH基团的糖, 式Ia或Ib的化合物,其中R是式IIa或IIb的相应糖的均匀溶液之一的基团之一,在30℃的存在下加热至75℃-100℃ (III)的MeX2(III)的金属盐,其中Me是Mg,Ca,Sr,Ba或Zn,X是Cl或Br,其可以含有或可以不含水 的结晶,并且在基于所用糖的2至20摩尔%的存在下,使用钼(VI)化合物。 该方法对于制备作为维生素B2的中间体的D-核糖是特别重要的。